<DOC>
	<DOC>NCT02401048</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy, safety and tolerability of the combination treatment of ibrutinib and MEDI4736 in patients with relapsed or refractory lymphomas.</brief_summary>
	<brief_title>A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Lymphomas</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, Follicular</mesh_term>
	<mesh_term>Lymphoma, B-Cell</mesh_term>
	<mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Pathologically documented relapsed or refractory diffuse large Bcell lymphoma (DLBCL) or follicular lymphoma (FL) Measurable disease sites on CT scan (&gt;1.5 cm in longest dimension) Adequate hematologic function: 1. Absolute Neutrophil Count &gt;1500 cells/mm3 2. Platelets &gt;50000 cells/mm3 3. Hemoglobin &gt;8.0 g/dL Adequate hepatic and renal function: 1. AST or ALT ≤2.5 x ULN 2. Bilirubin ≤1.5 x ULN 3. Estimated creatinine clearance (CockcroftGault) &gt;40 mL/min ECOG 0 or 1 Received prior therapies: ibrutinib, or other BTK inhibitor and/or antiPD1, antiPDL1, antiPDL2, antiCD137, or CTLA4 antibody Requires treatment or prophylaxis with a strong cytochrome P450 (CYP) 3A inhibitor Primary CNS lymphoma or evidence of CNS involvement by lymphoma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>